問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

曾彥寒TSENG, YEN-HAN
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

127Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾彥寒

List

157Cases

2024-03-28 - 2026-08-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-10-25 - 2026-12-31

Phase I

Active
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Condition/Disease

    Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Test Drug

    injective

Participate Sites
4Sites

Recruiting4Sites

2022-11-15 - 2034-07-12

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    AlectinibEntrectinibEntrectinibPralsetinibDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2022-06-01 - 2026-06-30

Phase II

A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

  • Condition/Disease

    Extensive-stage Small-cell Lung Cancer

  • Test Drug

    Ifinatamab Deruxtecan (I-DXd)

Participate Sites
6Sites

Recruiting6Sites

2024-08-01 - 2028-03-31

Phase II

A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    Osimertinib tablets 40 mg

Participate Sites
7Sites

Recruiting7Sites

2024-07-01 - 2027-08-31

Phase I/II

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    Vudalimab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2022-05-10 - 2026-08-04

Phase III

HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2024-10-01 - 2034-06-01

Phase III

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous(NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.

  • Condition/Disease

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%

  • Test Drug

    Relatlimab & Nivolumab Fixed Dose Vial (BMS-986213)

Participate Sites
2Sites

Recruiting2Sites

2024-01-01 - 2030-12-31

Phase III

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Carboplatin|Cisplatin|LY3537982|Pembrolizumab|Pemetrexed|Placebo

Participate Sites
14Sites

Recruiting14Sites

2018-02-01 - 2021-06-30

Phase III

A multicenter, randomized, double-blind, placebo-controlled, parallel-grouped Phase III trial to evaluate the efficacy and safety of Tezepelumab in adults and adolescents with poorly controlled severe asthma

  • Condition/Disease

    As an additional maintenance treatment for patients over 12 years old with severe asthma

  • Test Drug

    Tezepelumab

Participate Sites
4Sites

Terminated4Sites

1 11 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB